Porton Makes Debut at DCAT Week 2024 to Jointly Promote Industry Development

NEW YORK, NY - From March 18th to March 21st, 2024, Midtown New York City hosted the 96th Annual DCAT Week, renowned as one of the world's largest and most prestigious business events in the pharmaceutical industry. Over four days, hundreds of member companies engaged in high-level customer meetings, typically involving senior management or C-suite executives. This event is a premier gathering held annually in New York City for companies involved in the global Bio/Pharmaceutical manufacturing value chain.

On Monday, Porton Chairman & CEO, Oliver Ju, delivered a presentation at the DCAT Annual Membership Forum, an invite-only platform to highlight exciting company news within the DCAT Member Company network. Mr. Ju presented Porton’s exciting globalization strategy and layout blueprint, showcasing Porton’s new R&D and GMP production site in Slovenia as well as the state-of-the-art DS/DP and HPAPI facility in the United States. Additionally, the presentation also highlighted Porton’s focus on cutting-edge technologies and achievements in one-stop new capabilities like Tides, and how we could optimize process efficiency and cost control during R&D and manufacturing.

At this year's conference, Porton showcased our commitment to customer-centricity by offering innovative and reliable global solutions, reinforcing our leading position as a global CDMO service platform. This strategic focus aligns perfectly with our goal of introducing Porton's advanced technical expertise and client oriented CDMO services to customers in the United States. By participating in this prominent event, the company played a crucial role in establishing Porton as a go-to partner for addressing technical hurdles and launching groundbreaking drugs in the US market.